25.06.2012 • News • Lonza • BioWa • cell culture

Lonza, Biowa Sign License Agreements with FivePrime Therapeutics

FivePrime Therapeutics has entered into research and commercial agreements with Biowa and Lonza to use their Potelligent CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of Biowa's engineered glycosylation Potellingent Technology with the advantages of Lonza's proprietary GS Gene Expression Systems, which includes the industry-leading CHOK1SV cell line.

 

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Top-Feature